Historical Valuation
Iovance Biotherapeutics Inc (IOVA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.70 is considered Undervalued compared with the five-year average of -6.77. The fair price of Iovance Biotherapeutics Inc (IOVA) is between 3.57 to 4.79 according to relative valuation methord. Compared to the current price of 2.45 USD , Iovance Biotherapeutics Inc is Undervalued By 31.29%.
Relative Value
Fair Zone
3.57-4.79
Current Price：2.45
31.29%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Iovance Biotherapeutics Inc (IOVA) has a current Price-to-Book (P/B) ratio of 1.38. Compared to its 3-year average P/B ratio of 2.67 , the current P/B ratio is approximately -48.14% higher. Relative to its 5-year average P/B ratio of 3.56, the current P/B ratio is about -61.14% higher. Iovance Biotherapeutics Inc (IOVA) has a Forward Free Cash Flow (FCF) yield of approximately -35.17%. Compared to its 3-year average FCF yield of -25.40%, the current FCF yield is approximately 38.49% lower. Relative to its 5-year average FCF yield of -20.03% , the current FCF yield is about 75.56% lower.
P/B
Median3y
2.67
Median5y
3.56
FCF Yield
Median3y
-25.40
Median5y
-20.03
Competitors Valuation Multiple
AI Analysis for IOVA
The average P/S ratio for IOVA competitors is 10.60, providing a benchmark for relative valuation. Iovance Biotherapeutics Inc Corp (IOVA.O) exhibits a P/S ratio of 2.70, which is -74.57% above the industry average. Given its robust revenue growth of 15.20%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for IOVA
1Y
3Y
5Y
Market capitalization of IOVA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IOVA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is IOVA currently overvalued or undervalued?
Iovance Biotherapeutics Inc (IOVA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.70 is considered Undervalued compared with the five-year average of -6.77. The fair price of Iovance Biotherapeutics Inc (IOVA) is between 3.57 to 4.79 according to relative valuation methord. Compared to the current price of 2.45 USD , Iovance Biotherapeutics Inc is Undervalued By 31.29% .
What is Iovance Biotherapeutics Inc (IOVA) fair value?
IOVA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Iovance Biotherapeutics Inc (IOVA) is between 3.57 to 4.79 according to relative valuation methord.
How does IOVA's valuation metrics compare to the industry average?
The average P/S ratio for IOVA's competitors is 10.60, providing a benchmark for relative valuation. Iovance Biotherapeutics Inc Corp (IOVA) exhibits a P/S ratio of 2.70, which is -74.57% above the industry average. Given its robust revenue growth of 15.20%, this premium appears unsustainable.
What is the current P/B ratio for Iovance Biotherapeutics Inc (IOVA) as of Jan 10 2026?
As of Jan 10 2026, Iovance Biotherapeutics Inc (IOVA) has a P/B ratio of 1.38. This indicates that the market values IOVA at 1.38 times its book value.
What is the current FCF Yield for Iovance Biotherapeutics Inc (IOVA) as of Jan 10 2026?
As of Jan 10 2026, Iovance Biotherapeutics Inc (IOVA) has a FCF Yield of -35.17%. This means that for every dollar of Iovance Biotherapeutics Inc’s market capitalization, the company generates -35.17 cents in free cash flow.
What is the current Forward P/E ratio for Iovance Biotherapeutics Inc (IOVA) as of Jan 10 2026?
As of Jan 10 2026, Iovance Biotherapeutics Inc (IOVA) has a Forward P/E ratio of -4.17. This means the market is willing to pay $-4.17 for every dollar of Iovance Biotherapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Iovance Biotherapeutics Inc (IOVA) as of Jan 10 2026?
As of Jan 10 2026, Iovance Biotherapeutics Inc (IOVA) has a Forward P/S ratio of 2.70. This means the market is valuing IOVA at $2.70 for every dollar of expected revenue over the next 12 months.